Concord Medical Announces Divestment of Chang'an Hospital

Concord Medical Services Holdings Limited ("Concord Medical" or the "Company")

, an operator of specialty cancer hospitals and the largest network of radiotherapy and diagnostic imaging centers in China, today announced that the Company has, through its subsidiaries, entered into a definitive agreement to sell 52% equity interest in Chang'an Hospital to the owner of the 48% equity, for a total consideration of RMB398 million (US$64.8 million, or $1=RMB 6.1376). The consideration also includes the sale of ownership interests in Chang'An CMS International Cancer Center ("CCICC"), a specialized cancer diagnosis and treatment center established between Concord Medical and Chang'an Hospital in July 2010. This 100% cash transaction has been approved by the boards of directors of both parties. The closing of this transaction is subject to relevant government approvals and is expected to be completed by the end of 2014. Concord's Board believes the transaction price reflects fair market value for Chang'an Hospital based on valuation report by an independent third-party appraisal company engaged by the Company. After the closing of this transaction, the Company will continue to cooperate with Chang'an Hospital on hospital management, oncology department and talent training. Both sides have agreed to hold discussions on future collaboration and to sign collaborative agreements in the future. "Our divestment of Chang'an Hospital allows Concord to more fully concentrate on our efforts to build a nationwide network of diagnosis and treatment centers and specialized cancer hospitals," Dr. Jianyu Yang, Chairman and CEO of Concord Medical, comments. "The proceeds from this transaction will be used to fund the construction of our current projects as well as to pay off some current debt. Going forward, we expect to open five free-standing radiotherapy cancer centers and to begin construction on one to two Level-III premium cancer specialty hospitals in 2015."